Equities Analysts Offer Predictions for SCPH FY2024 Earnings

scPharmaceuticals Inc. (NASDAQ:SCPH) – Investment analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of scPharmaceuticals in a report released on Thursday, November 14th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($1.43) per share for the year, down from their previous forecast of ($1.33). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for scPharmaceuticals’ Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.45 EPS.

Separately, Craig Hallum cut their target price on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday.

scPharmaceuticals Stock Up 3.0 %

SCPH opened at $3.46 on Monday. The business has a 50 day moving average price of $4.46 and a two-hundred day moving average price of $4.48. The company has a quick ratio of 3.66, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The company has a market cap of $173.14 million, a PE ratio of -1.82 and a beta of 0.15. scPharmaceuticals has a 52 week low of $3.08 and a 52 week high of $6.71.

Institutional Investors Weigh In On scPharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Rubric Capital Management LP grew its holdings in shares of scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after acquiring an additional 1,250,000 shares during the period. AIGH Capital Management LLC grew its holdings in shares of scPharmaceuticals by 3.4% in the 2nd quarter. AIGH Capital Management LLC now owns 3,504,365 shares of the company’s stock worth $15,244,000 after acquiring an additional 115,206 shares during the period. King Luther Capital Management Corp grew its holdings in shares of scPharmaceuticals by 0.9% in the 3rd quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock worth $10,150,000 after acquiring an additional 20,650 shares during the period. Suvretta Capital Management LLC acquired a new stake in scPharmaceuticals during the 3rd quarter valued at $9,343,000. Finally, Thrivent Financial for Lutherans grew its holdings in scPharmaceuticals by 1.4% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after buying an additional 14,866 shares during the last quarter. Institutional investors and hedge funds own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.